Passage Bio to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Passage Bio (NASDAQ: PASG) said management will present and hold investor meetings at two upcoming conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference on Feb 26, 2026 (virtual; presentation 8:40 a.m. ET) and TD Cowen 46th Annual Health Care Conference on Mar 4, 2026 (Boston; presentation 1:50 p.m. ET).
A live webcast will be available on the company's Investors & Media page and a replay will be accessible for 30 days after each event.
Positive
- None.
Negative
- None.
News Market Reaction – PASG
On the day this news was published, PASG gained 2.32%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
PHILADELPHIA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences:
Oppenheimer 36th Annual Healthcare Life Sciences Conference
Format: Management will participate in a presentation and investor meetings
Date: Thursday, February 26, 2026
Presentation Time: 8:40 a.m. ET
Location: Virtual
TD Cowen 46th Annual Health Care Conference
Format: Management will participate in a presentation and investor meetings
Date: Wednesday, March 4, 2026
Presentation Time: 1:50 p.m. ET
Location: Boston, MA
A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.
To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: passagebio.com.
For further information, please contact:
Investors:
Stuart Henderson
Passage Bio
shenderson@passagebio.com
Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
mikebeyer@sambrown.com